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Abstract
Background & Aims—RAC1 is a GTPase that has an evolutionarily conserved role in
coordinating immune defenses, from plants to mammals. Chronic inflammatory bowel diseases
(IBD) are associated with dysregulation of immune defenses. We studied the role of RAC1 in IBD
using human genetic and functional studies and animal models of colitis.
Methods—We used a candidate gene approach to HapMap-Tag single nucleotide polymorphisms
(SNPs) in a discovery cohort; findings were confirmed in 2 additional cohorts. RAC1 mRNA
expression was examined from peripheral blood cells of patients. Colitis was induced in mice with
conditional disruption of Rac1 in phagocytes by administration of dextran sulphate sodium (DSS).
Results—We observed a genetic association between RAC1 with ulcerative colitis (UC) in a
discovery cohort, 2 independent replication cohorts, and in combined analysis for the SNPs
rs10951982 (Pcombined UC = 3.3 × 10–8, odds ratio [OR]=1.43 [1.26–1.63]) and rs4720672
(Pcombined UC=4.7 × 10–6, OR=1.36 [1.19–1.58]). Patients with IBD who had the rs10951982
risk allele had increased expression of RAC1, compared to those without this allele. Conditional
disruption of Rac1 in macrophage and neutrophils of mice protected them against DSS-induced
colitis.
Conclusion—Studies of human tissue samples and knockout mice demonstrated a role for the
GTPase RAC1 in the development of UC; increased expression of RAC1 was associated with
susceptibility to colitis.
Keywords
innate immunity; Crohn's disease; CD; Rac-1 knockout
Introduction
IBD is a chronic relapsing and remitting disease that affects 1 in 250 individuals of
European ancestry. Although the exact etiology of IBD is unknown, it is speculated that IBD
occurs in genetically susceptible individuals as a result of dysregulated immune response to
gut flora after exposure to an as yet unidentified environmental stimulus1. Genetic
association studies have identified innate immunity as a critical component in the
development of IBD2–8. However, these studies have identified only 23% of the
susceptibility determinants for CD9 and 16% for UC10.
RAC1 belongs to the Ras superfamily of GTP-binding proteins that act as “molecular
switches” and influence a number of key cellular functions critical for innate immunity11
including NOD2 and TLR2 regulation12, leukocyte chemotaxis13, barrier defence14, and
bacterial killing15. RAC1 function is also disrupted by multiple bacterial cytotoxins16.
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Furthermore, RAC1 is a target of the commonly used IBD treatment azathioprine, the effects
of which are thought to be mediated through T cell apoptosis17 and altered phagocyte
chemotaxis to sites of intestinal inflammation18. The importance of RAC1 in innate
immunity as seen through its conservation from plants19 to mammals led to our detailed
exploration of the RAC1 gene involvement in IBD.
Materials and Methods
SNP Analysis and Genotyping
International HapMap project20 (http://www.hapmap.org) Caucasian (CEU) Phase II data
were used to select tag SNPs (MAF > 1%) that span the RAC1 gene and flanking regions
through the “Tagger” software program21. Twelve tag SNPs covering RAC1 region
(Chromosome 7, 6386318 to 6411760) were captured with r2 > 0.8 (1 SNP was removed
during QC because the MAF was < 1%; See Supplemental Methods). Genotype analysis of
samples was done using the Illumina® Goldengate Custom Chip genotyping system
(Toronto discovery) and Taqman (North America Replication and Scotland Validation) at
The Centre for Applied Genomics, Hospital for Sick Children, Toronto and the University of
Edinburgh.
Subjects (for Quality Control, and Population Stratification please see Supplemental
Methods)
All subjects in this study were of European descent by self-reporting of ethnic heritage. All
probands had a confirmed diagnosis of IBD and fulfilled standard diagnostic criteria.
Phenotypic characterization was based on the Montreal classification22. Perianal disease
included only those CD patients with perianal abscess and/or fistulae. Study subject
phenotypic information and DNA samples were obtained with institutional review ethics
board approval for IBD genetic studies at the Hospital for Sick Children and Mount Sinai
Hospital in Toronto. Replication cohorts had REB approval for genetic and phenotypic
studies at the individual institutions. Written informed consent was obtained from all
participants.
The discovery cohort included patients recruited from the Hospital for Sick Children and Mt
Sinai Hospital in Toronto with local and NIDDK control individuals. The first replication
cohort consisted of 1836 Caucasian individuals from North American including 443 CD and
477 UC patients, and 916 controls (NIDDK patients recruited from Chicago and Pittsburgh
with North American control individuals obtained from the Centre for Applied Genomics).
The second cohort consisted of 2449 individuals exclusively recruited from Scotland
including 691 CD and 615 UC patients, and 1143 controls. All patients and controls
individuals were non-related Caucasian individuals. Only two RAC1 SNPs were genotyped
in the replication cohorts and both had call rates greater than 98% in both cohorts. Part of
these cohorts have been used in previous GWAS including the all the NIDDK patients in the
North American replication523 and 374 individual from Scotland in the Pediatric IBD
GWAS24. None of the replication cohort control individuals were genotyped in previous
IBD GWAS.
Preliminary Analysis
HAPLOVIEW25 was used to obtain LD patterns, obtaining descriptive statistics and
summaries of the SNPs. PLINK version 1.0626 was used to test for Hardy-Weinberg
equilibrium (HWE) for each marker based on Pearson's chi-square test. Descriptive statistics
of demographic variables were generated using SAS version 9.2 (SAS institute, Cary, NC).
The Wilcoxon Rank Sum Test and Chi-square test were used to identify differences in
demographic variables between subgroups.
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Association Analysis
The analysis was applied in three stages. In stage one, association analyses were applied to
detect the associations with the 11 RAC1 SNPs (1 SNP was removed during QC because the
MAF was < 1%; See Supplemental Methods) and IBD, CD, and UC vs. healthy controls
(HC). Logistic regression models were applied for the additive genetic model, and Pearson
chi-square tests were applied for dominant and recessive genetic models. Although we used
an additive genetic model for primary analysis27 we also explored dominant and recessive
genetic models for sensitive analysis. Throughout the report the p-values are the dominant
genetic model p-value. Odds ratios (OR) and 95% confidence intervals (CI) were estimated
for the disease compared to the control group. The association, adjusting for selected
principal component vectors from the EIGENSTRAT analysis, was tested using conditional
logistic regression (SAS v9.2, Cary, NC).
In stage two, the 2 RAC1 SNPs identified from the discovery cohort were genotyped in a
replication cohort (North America) and independent validation cohort (Scotland).
Independent analysis was applied on the replication cohort and validation cohort. Combined
effect estimates from all three IBD cohorts were estimated using a logistic regression model.
All P-values are two-sided.
In stage 3, the confirmed RAC1 SNPs were further explored. Haplotype analysis was applied
on this region on multiple marker blocks. Imputation of an additional 73 ungenotyped SNPs
in the RAC1 region was performed using released Phase II/III CEU HapMap data
(BEAGLE). The imputed SNPs were analyzed on the IBD phenotypes using an additive
genetic model.
Subgroup Analysis
In addition to comparing IBD, CD, and UC to HC, we applied subgroup analysis to evaluate
the genetic effect on the disease risk of the IBD sub-population according to the Montreal
Classification system. The sub-population comparisons were applied for each of the genetic
markers on ileal only (L1), colonic only (L2), ileo-colonic (L3), ileal any (L1/L3), colon
only (L2 plus UC), colon any (L2/L3 plus UC), perianal, and early onset IBD patients
(diagnosis age < 19) vs. HC. Different genetic models were used to test single marker
associations between each of the subgroups. The analyses were applied for the discovery
cohort, North American replication cohort, Scottish replication cohort, and the pooled
samples separately.
Animal Experimentation
Rac1-KO mice were generated, bred and genotyped (mixed Sv129 black 6 and Balb/c
background) as previously described28. Mice used in these experiments were between 8 and
12 wks old, and all control mice were littermates of the Rac1-KO mice. Rac1-KO mice
exhibited no obvious phenotype. Mice were housed in a pathogen free environment and fed
standard diet with free access to water. All experiments were approved by the Animal Care
Ethics panel at the University of Toronto.
DSS Model
Dextran sodium sulphate (DSS) experiments were performed as previously described29. For
the Rac1-KO experiments 12 KO and 18 WT mice were treated with 5% DSS in their
drinking water for 7 days. Mice were monitored daily for weight loss, stool consistency,
rectal bleeding and general appearance. For further DSS, Cytokine, and MPO methods
please see Supplemental Methods.
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Results
Genetic Studies
Candidate Gene Approach—We first examined the role of RAC1 in IBD using a
candidate gene approach. After strict quality control (QC; 1 SNP was removed during QC
because the MAF was < 1%; See Supplemental Methods) measures, 11 RAC1 tag SNPs
(Supplemental Figure 1) were successfully genotyped in the discovery cohort consisting of
2049 subjects (656 CD, 544 UC, and 849 controls; Supplementary Table 1A). The
rs10951982 RAC1 SNP was significantly associated with IBD after Bonferroni correction
threshold for 11 SNPs examined for IBD, CD and UC (α = 1.5 × 10−3; Table 1 shows the
association for discovery SNPs based on the minor allele). rs10951982 is not located in a
known regulatory element or in strong LD (r2 > 0.25) with any HapMap SNP located in
other genes on Chromosome 7.
Genetic Replication—To confirm this association, we examined rs10951982 and
rs4720672 in two independent cohorts. The replication cohort was comprised of 1836
Caucasian subjects including 443 CD and 477 UC patients, and 916 controls recruited from
North America and a second validation cohort from Scotland comprised of 2449 Caucasian
subjects including 691 CD and 615 UC patients, and 1143 controls (Supplementary Table
1B and 1C). The signal for IBD and UC was replicated in both cohorts with similar ORs and
minor allelic frequency (Table 2). Further exploration of genetic models showed that the
signal was strongest in the dominant model (reported here and Supplemental Table 3).
Combined analysis (1790 CD and 1636 UC patients, and 2908 controls) showed that both
SNPs were significantly associated with IBD, CD, and UC (Pcombined IBD = 4.2 × 10−7, OR
= 1.29 (1.17–1.44), Pcombined CD = 3.7 × 10−3, OR = 1.19 (1.06–1.34), and Pcombined UC =
3.3 × 10−8, OR = 1.43 (1.26–1.63) for rs10951982; and Pcombined IBD = 7.7 × 10−7, OR =
1.34 (1.17–1.47), Pcombined CD = 3.7 × 10−4, OR = 1.26 (1.11–1.44), and Pcombined UC = 4.7
× 10−6, OR= 1.36 (1.19–1.58) for rs4720672).
As rs10951982 and rs4720672 are in LD (r2 = 0.64, controls), we applied haplotype
analysis30. The haplotype of this two-SNP block is significantly associated with IBD, CD,
and UC (PIBD = 9.1 × 10−3, PCD = 5.0 × 10−2, and PUC = 3.1 × 10−2, haplotype omnibus
test). Further haplotype analysis on different RAC1 SNP blocks did not show significant
associations (data not shown).
Genotype-Phenotype Analysis—As the initial analysis indicated that the genetic signal
was strongest in IBD and UC, the role of these SNPs was examined by disease location
using the Montreal Classification22 (Table 3). We analyzed “any” colonic IBD (combined
UC, colonic only CD (L2), and ileo-colonic CD (L3)) and found significant association with
both SNPs in the combined analysis (Pcombined = 7.8 × 10−8, OR= 1.33 (1.20–1.49) for
rs10951982; and Pcombined = 1.6 × 10−7, OR= 1.35 (1.20–1.51) for rs4720672). These SNP
remained significant after Bonferroni correction (Bonferroni correction threshold: for 11
SNP examined in 8 IBD sub-phenotypes; α = 5.6 × 10−4). Further significant association
was found with colonic only IBD (combined UC and colonic only CD (L2)) and early onset
IBD (diagnosis < 19 years of age).
Imputation Analysis—We next imputed 73 SNPs in the RAC1 region not initially
genotyped using released Phase II/III CEU HapMap data to identify any additional
significant SNPs in our discovery cohort. Imputation analysis revealed multiple HapMap
SNPs with nominal significant levels of association (Figure 1A for IBD and Supplemental
Figure 2 for UC and CD). Three SNPs located in intron 3 of RAC1 in strong LD (r2 > 0.80)
with rs10951982 showed the strongest association with IBD and UC (for IBD: rs836472, P
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= 1.2 × 10−3, OR = 1.33; rs1880118, P = 9.8 × 10−4, OR = 1.33; and rs12536544, P = 1.2 ×
10−3, OR = 1.33). Together these data implicate this region of RAC1 as harboring the causal
variant; however, the imputed SNPs are based on in silico analysis and further sequencing in
this region is required to determine the causal variant(s).
RAC1 Expression—Our study indicates that RAC1 rs10951982 risk allele increases the
susceptibility to the development of colonic IBD. A previous study demonstrated that SNPs
in the RAC1 gene region are in an expression quantitative trait loci (eQTLs) in
lymphoblastoid cell lines (Figure 2A)31. The area of maximal LOD score (3.3 – 4.3) on
chromosome 7 occurs in the RAC1 gene region with several SNPs (rs37279790, rs836472,
rs1880118, rs12536544, and rs10951983) in strong linkage disequilibrium to rs10951982 (r2
of 0.82 to 1.0). The additive effect for the major allele corresponded to a cis-acting
regulatory effect with an increase in standard deviation units for RAC131 (Figure 2A and
Supplemental Table 4). Furthermore, mRNA from freshly isolated peripheral blood cells
(PBCs) in 16 IBD patients with colonic disease showed increased RAC1 expression based on
genotype (Figure 2B). Carriage of the risk `G' allele resulted in increased RAC1 expression
(comparison of normalized expression for GG (7 patients) / AG (5 patients) to AA (4
patients) using non-parametric comparison and Wilcoxon exact test P = 0.008; and AA vs
GG Wilcoxon exact test P = 0.012). These results indicate that carriage of the risk allele of
rs10951982 results in increased RAC1 expression. There were no differences in RAC1
splicing based on genotype in these patients (data not shown). Further expression analysis is
required to determine the effect of these SNPs on RAC1 expression, splicing, and mRNA
stability in both healthy individuals and IBD patients.
Animal Studies: Rac1 Conditional Knockout Mice Studies—As Rac1 knockouts
are embryonic lethal in mice32, we next examined the neutrophil and macrophage
conditional Rac1 knockout (Rac1-KO) mice28. These mice had no obvious colonic
phenotype with normal bowel histology although they did show increased MPO activity
(Figure 3B). As shown in Figure 3A, the Rac1-KO mice were protected from developing
DSS-induced colitis. Rac1-KO mice show decreased weight loss after 6 days (P < 0.01;
Wilcoxon rank sum test). WT mice began bleeding after day 4 with 10/18 mice bleeding on
day 7. In comparison, only 1/12 Rac1-KO was bleeding on day 7 (P = 0.0051; log rank test
= 7.3, hazard ratio 4.6, 95% CI 1.5–14). WT mice had significantly worse DAI scores
starting on day 4 (P < 0.05 on day 4, and P < 0.001 on days 5, 6, and 7 Wilcoxon rank sum
test). Comparison of the distal colon on day seven of DSS treatment showed reduced
histological scores with fewer ulcers in the distal colonic in the Rac1-KO group (P=0.008
analyzed as a dichotomous variable with a cutoff of 0 – 2 or > 3 ulcers using Fisher's exact
test; Supplemental Figure 3). Neutrophil migration into the colon was reduced in the Rac1-
KO mice compared to WT as assessed by MPO activity (Figure 3C. P < 0.01; Wilcoxon
rank sum test). Cytokine profiles for colonic lystates from Rac1-KO mice treated with DSS
showed significantly reduced level of the proinflammatory cytokine IL-1β and the
neutrophil chemokine KC compared to WT mice (Figure 3C; P < 0.05; Mann Whitney test
Two Tailed). Furthermore, there was impaired up-regulation of proinflammatory cytokines
including IL-1β, IL-12 and TNFα in response to DSS induced colitis as compared to WT (P
< 0.05, Mann Whitney test Two Tailed; Supplemental Figure 4). Splenocytes isolated from
DSS-treated Rac1-KO mice and stimulated with lipopolysaccharide (LPS) also showed a
similar decrease in production of inflammatory cytokines (Supplemental Figure 5) further
demonstrating the reduced inflammation in these KO mice.
Discussion
Recent IBD GWAS have identified innate immunity as a critical component in the
pathogenesis of IBD2–8. The identification of RAC1's association with IBD further
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strengthens this link with innate immunity. The number of IBD susceptibility genes has
increased dramatically due to meta-analysis of recent GWAS and the signal for RAC1 has
not been reported to date. However, in the 1st International IBD Genetics Consortium
(IIBDGC) meta-analysis for UC, SNPs in strong LD (r2 > 0.80; and identified in our
imputation analysis Figure 1A) to our reported SNP (rs10951982) showed strong association
to UC (rs12536544, Pmeta = 8.80 × 10−5; rs836472, Pmeta = 2.60 × 10−5; rs1880118, Pmeta =
6.3 × 10−4; and rs10951983, UC Pmeta = 1.2 × 10−4)10. Although these SNPs have not yet
been reported due to the stringent criteria for replication in that UC meta-analysis10, these
meta-analysis results strongly implicate RAC1 as a novel UC susceptibility gene.
Furthermore, the RAC1 SNP rs12536544 genotyped in the meta-analysis was at the
maximum eQTL for RAC1 as shown in Figure 2A (P = 10−7) indicating that the risk allele
for these SNPs increased RAC1 expression. Interestingly, this novel genetic association is
also found with the colonic IBD (UC and colonic CD) phenotype, a phenotype that has yet
to be explored in IBD GWAS.
We observed that reduction or loss of Rac1 expression through conditional neutrophil/
macrophage KO resulted in protection from the development of DSS induced colitis. We
chose the DSS model as it has recently been shown to be a reasonable model of UC33. This
protection from DSS induced colitis was accompanied by a reduction in MPO, an indirect
marker of neutrophil colonic infiltration, and a reduction in the colonic proinflammatory
cytokine IL-1β and the neutrophil chemokine KC. We have previously shown that loss of
Rac1 in these mice results in profound defects in inflammatory recruitment and migration to
chemotactic stimuli28. The down-regulation of the neutrophil chemokine KC would also
result in decreased neutrophil migration and reduced inflammation into the intestine34.
Therefore, it is possible that the protection from DSS induced colitis in these mice is due to
delayed neutrophil infiltration as observed when neutrophil recruitment is impaired through
CXCR2 blocking antibodies35. This is also consistent with other animal models of
inflammation where loss of Rac1 function leads to decreased neutrophil recruitment leading
to attenuation of inflammation28, 36, 37.
Although the causal variant has not been established in this study, expression datasets22 and
our patient's expression studies demonstrates that the RAC1 risk allele identified here
increases RAC1 expression. These human expression experiments are complemented by our
animal model experiments that show that decreased Rac1 activity or loss Rac1 expression
leads to protection from the development of DSS induced colitis. The cytokine profile
observed from colonic lysates from DSS treated animals with conditional macrophage/
neutrophil Rac1-KO demonstrated defective proinflammatory production. Overall, these
results suggest that carriage of the RAC1 risk allele results in higher expression of RAC1
leading to increased neutrophil recruitment into the colon and subsequent increased
proinflammatory cytokine expression in colonic. Along with RAC1 dependent T-cell
apoptosis17, one of the proposed mechanisms for the medication commonly used to maintain
IBD patients in remission, azathioprine, is through inhibition of neutrophil trafficking into
the colon18. Therefore it is intriguing to speculate that patients carrying the RAC1 risk allele
have higher levels of RAC1 expression with increased neutrophil migration into the colon
and that these patients may benefit from treatment with azathioprine.
RAC1 is expressed in most cell types and has divergent and critical role in numerous
cellular pathways. The functional studies presented here focus on its role in the neutrophil-
macrophage cell lineage. It is also plausible that the association of RAC1 with IBD is
mediated through an alternate pathway not examined here. The divergent functions of RAC1
in innate immunity, barrier defense, and T cell apoptosis makes further study of this protein
important to our understanding of IBD.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RAC1 Imputation Analysis
Regional blots plot of the negative decadic logarithm of the P-values of SNPs in the RAC1
region including both genotyped (diamond) and imputation (*) SNPs, based on the 2049
individuals from the discovery cohort. In IBD the strongest signal comes from 3 SNPs
(rs836472, rs1880118, rs12536544) located at 6401429 to 6402426 of Chromosome 7 that
are in strong LD (r2 > 0.80) with rs10951982. RAC1 gene is depicted below LD plot with
genotyed SNP in bold and r2 SNP map.
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Figure 2. RAC1 Expression Based on Genotype
(A) Plot of LOD score (y-axis) and SNP position of each chromosome (x-axis). The eQTL
maximal LOD score on chromosome 7 is the RAC1 SNP (rs12536544) that is in strong
disequilibrium to rs10951982 (r2 of 0.82 to 1.0).
(B) RAC1 expression from mRNA isolated from PBCs from 16 IBD patients with colonic
disease based on rs10951982 genotype. `G' allele is the risk allele. Expression was
normalized to β-actin expression. Wilcoxon exact test.
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Figure 3. Impact of impairing Rac1 function in DSS induced colitis in mice
(A) Rac1-KO. Left Panel graphs changes in weight with DSS treatment. Middle Panel
shows changes in rectal bleeding. # at risk indicates number of mice not bleeding at each
time point. Right Panel shows Disease Activity Index. (Error bars represent SEM).
(B) Colonic MPO Activity. Colonic neutrophil infiltration was measured by MPO activity.
MPO activity was assessed in the distal colon of WT mice (WT + water), Rac1-KO mice
(Rac1-KO + water), and Rac1-KO mice treated with 5% DSS (Rac1-KO + DSS). (Wilcoxon
rank sum test; Error bars represent SEM).
(C) Colonic Cytokine Assay. Cytokine assays performed using MESO scale discovery
mouse TH1/TH2 9-plex assay kit. (Mann Whitney test Two Tailed; Error bars represent
SEM).
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